IDefine attends Ultragenyx Rare Entrepreneur Bootcamp Ultragenyx, a biopharmaceutical company involved in the development of novel products for treatment of rare genetic diseases, has been advising rare disease non-profits on an ad hoc basis for years. However, in 2017, Ultragenyx decided to develop a more formal curriculum on the rare drug development process, and the “Rare Bootcamp” was born. Since then, more than 65 patient and family organizations have participated in the Bootcamp event series. To ensure that the bootcamps are personal and impactful, only a small number of organizations that have typically already started their drug development journey are invited to attend. IDefine was invited and represented at the two-and-a-half-day event in Novato, Calif., by Geoff Rhyne, CEO, and Eric Scheeff, chief scientific officer (CSO). “It's an honor to be invited because it means that IDefine is viewed as ready enough as an organization to really hear this message,” said Scheeff. “It was exciting to get the invitation and a golden opportunity that we couldn't miss. My expectations were high, and they were massively exceeded.” | |
